Page 1176 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1140 PART NINE Transplantation

Please check your eBook at https://expertconsult.inkling.com/ 22. Anderson BE, McNiff J, Yan J, et al. Memory CD4+ T cells do not induce
for self-assessment questions. See inside cover for registration graft-versus-host disease. J Clin Invest 2003;112:101–8.
details. 23. Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce
graft-versus-host disease is a result of an abortive alloresponse. Blood
2007;109:3115–23.
REFERENCES 24. Rowley SD, Donato ML, Bhattacharyya P. Red blood cell incompatible
allogeneic hematopoietic progenitor cell transplantation. Bone Marrow
1. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and Transplant 2011;46:1167–85.
mortality of HLA-matched unrelated donor hematopoietic cell 25. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev
transplantation after nonmyeloablative and myeloablative conditioning: Clin Oncol 2016;13:370–83.
influence of pretransplantation comorbidities. Blood 2004;104:961–8. 26. Bachireddy P, Burkhardt UE, Rajasagi M. Haematological malignancies: at
2. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch the forefront of immunotherapeutic innovation. Nat Rev Cancer
increases mortality after myeloablative unrelated allogeneic hematopoietic 2015;15:201–15.
cell transplantation. Blood 2014;124:2596–606. 27. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab
3. Confer DL, Abress LK, Navarro W, et al. Selection of adult unrelated in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med
hematopoietic stem cell donors: beyond HLA. Biol Blood Marrow 2015;372:311–19.
Transplant 2010;16:S8–S11. 28. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with
4. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the ipilimumab to treat relapse of malignancy after allogeneic hematopoietic
bedside. Blood 2009;114:4327–36. cell transplantation. Blood 2009;113:1581–8.
5. Bleakley M, Riddel SR. Molecules and mechanisms of the graft-versus- 29. Leitch HA, Connors JM. Vaccine therapy for non-Hodgkin’s lymphoma
leukaemia effect. Nat Rev Cancer 2004;4:371–80. and other B-cell malignancies. Curr Opin Investig Drugs 2005;6:
6. Kolb H-J. Graft-versus-leukemia effects of transplantation and donor 597–604.
lymphocytes. Blood 2008;112:4371–83. 30. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus
7. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of bone marrow from unrelated donors. N Engl J Med 2012;367:1487–96.
graft-versus-host disease in human recipients of marrow from 31. Vasconcelos ZF, Santos BM, Costa ES, et al. T-lymphocyte function from
HLA-matched sibling donors. Transplantation 1974;18:295–304. peripheral blood stem-cell donors is inhibited by activated granulocytes.
8. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on Cytotherapy 2003;5:336–45.
acute GvHD grading. Bone Marrow Transplant 1995;15:825–8. 32. Offner F, Schoch G, Fisher LD, et al. Mortality hazard functions as related
9. Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived to neutropenia at different times after marrow transplantation. Blood
metabolites modulate intestinal epithelial cell damage and mitigate 1998;88:4058–62.
graft-versus-host disease. Nat Immunol 2016;17:505–13. 33. Rowley SD, Zuehlsdorf M, Braine HG, et al. CFU-GM content of bone
10. Schwartz R, Dameshek W. Drug-induced immunological tolerance. marrow graft correlates with time to hematologic reconstitution
Nature 1959;183:1682–3. following autologous bone marrow transplantation with
11. Berenbaum MC, Brown IN. Prolongation of homograft survival in mice 4-hydroperoxycyclophosphamide purged bone marrow. Blood
with single doses of cyclophosphamide. Nature 1963;200:84. 1987;70:271–5.
12. Robinson TM, O’Donnell PV, Fuchs EJ, et al. Haploidentical 34. Ringden O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure
bone marrow and stem cell transplantation: experience with in recipients of HLA-identical bone marrow or peripheral blood
post-transplantation cyclophosphamide. Semin Hematol 2016;53:90–7. stem cell transplants with high CD34 cell doses. Br J Haematol
13. Yeager AM, Vogelsang GB, Jones RJ, et al. Induction of cutaneous 2003;121:874–85.
graft-versus-host disease by administration of cyclosporine to patients 35. Heimfeld S. HLA identical stem cell transplant: is there an optimal CD34
undergoing autologous bone marrow transplantation for acute myeloid cell dose? Bone Marrow Transplant 2003;31:839–45.
leukemia. Blood 1992;79:3031–5. 36. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide
14. Keung YK, Beaty MW, Pettenati M, et al. Possible role of engraftment compared with total-body irradiation plus cyclophosphamide before
syndrome and autologous graft-versus-host disease in myelodysplastic marrow transplantation for myeloid leukemia: long-term follow-up of 4
syndrome after autologous stem cell transplantations: retrospective randomized studies. Blood 2001;98:3569–74.
analysis and review of the literature. Clin Lymphoma Myeloma Leuk 37. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in
2010;10:129–33. DLA-identical littermate dogs given sublethal total body irradiation
15. Pidala J, Kim J, Anasetti C, et al. The global severity of chronic before and pharmacological immunosuppression after marrow
graft-versus-host disease, determined by National Institutes of Health transplantation. Blood 1997;89:3048–54.
consensus criteria, is associated with overall survival and non-relapse 38. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell
mortality. Haematologica 2011;96:1678–84. transplantation in older patients with hematologic malignancies:
16. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemia effect of replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
graft-versus-host disease in human recipients of allogeneic-marrow grafts. Blood 2001;97:3390–400.
N Engl J Med 1979;300:1068–73. 39. Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with
17. van den Brink MRM, Porter DL, Giralt S, et al. Relapse after allogeneic hematopoietic stem cell transplantation in the treatment of follicular
hematopoietic cell therapy. Biol Blood Marrow Transplant lymphoma: an evidence-based review. Biol Blood Marrow Transplant
2010;16:S138–S145. 2010;16:443–68.
18. Jacoby E, Yang Y, Qin H, et al. Murine allogeneic CD19 CAR T cells 40. Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy
harbor potent antileukemic activity but have the potential to mediate with hematopoietic stem cell transplantation in the therapy of
lethal GVHD. Blood 2016;127:1361–70. myelodysplastic syndromes: an evidence-based review. Biol Blood
19. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions Marrow Transplant 2009;15:137–72.
in 140 patients with relapsed malignancy after allogeneic bone marrow 41. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with
transplantation. J Clin Oncol 1997;15:433–44. autologous transplantation for relapsed large B-cell lymphoma in the
20. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for rituximab era. J Clin Oncol 2010;28:4184–90.
relapsed chronic myelogenous leukemia: prognostic relevance of the 42. Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt’s and
initial cell dose. Blood 2002;100:397–405. Burkitt-like non-Hodgkin’s lymphoma – outcome for patients treated
21. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene- with high-dose therapy and autologous stem-cell transplantation in first
engineered donor lymphocytes after family haploidentical haematopoietic remission or at relapse: results from the European Group for Blood and
stem-cell transplantation for leukaemia (the TK007 trial): a Marrow Transplantation. J Clin Oncol 1996;14:2465–72.
non-randomised phase I-II study. Lancet Oncol 2009;10:489–500.